529 related articles for article (PubMed ID: 30355775)
1. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
2. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
[TBL] [Abstract][Full Text] [Related]
3. BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.
Mirakhur B; Pavel ME; Pommier RF; Fisher GA; Phan AT; Massien C; Liyanage N; Lowenthal SP; Vinik AI
Endocr Pract; 2018 Aug; ():. PubMed ID: 30084687
[TBL] [Abstract][Full Text] [Related]
4. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
[TBL] [Abstract][Full Text] [Related]
5. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Gomez-Panzani E; Ruszniewski P;
Endocr Relat Cancer; 2016 Mar; 23(3):191-9. PubMed ID: 26743120
[TBL] [Abstract][Full Text] [Related]
7. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
Caplin ME; Pavel M; Phan AT; Ćwikła JB; Sedláčková E; Thanh XT; Wolin EM; Ruszniewski P;
Endocrine; 2021 Feb; 71(2):502-513. PubMed ID: 33052555
[TBL] [Abstract][Full Text] [Related]
8. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
[TBL] [Abstract][Full Text] [Related]
9. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Fisher GA; Wolin EM; Liyanage N; Pitman Lowenthal S; Mirakhur B; Pommier RF; Shaheen M; Vinik A;
Oncologist; 2018 Jan; 23(1):16-24. PubMed ID: 29038234
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.
Ito T; Honma Y; Hijioka S; Kudo A; Fukutomi A; Nozaki A; Kimura Y; Motoi F; Isayama H; Komoto I; Hisamatsu S; Nakajima A; Shimatsu A
Invest New Drugs; 2017 Aug; 35(4):499-508. PubMed ID: 28470558
[TBL] [Abstract][Full Text] [Related]
11. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
[TBL] [Abstract][Full Text] [Related]
12. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
13. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.
Kang J; Yoo C; Hwang HS; Hong SM; Kim KP; Kim SY; Hong YS; Kim TW; Ryoo BY
Invest New Drugs; 2019 Aug; 37(4):763-770. PubMed ID: 30536151
[TBL] [Abstract][Full Text] [Related]
15. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.
Eriksson B; Renstrup J; Imam H; Oberg K
Ann Oncol; 1997 Oct; 8(10):1041-4. PubMed ID: 9402179
[TBL] [Abstract][Full Text] [Related]
16. [Antiproliferative Effect of Somatostatin Analogs - Data Analyses and Clinical Applications in the Context of the CLARINET Study].
Bencsiková B
Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
[TBL] [Abstract][Full Text] [Related]
17. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
Barnes JI; Lin JK; Gupta D; Owens DK; Goldhaber-Fiebert JD; Kunz PL
J Natl Compr Canc Netw; 2020 Sep; 18(9):1200-1209. PubMed ID: 32886901
[TBL] [Abstract][Full Text] [Related]
19. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
[TBL] [Abstract][Full Text] [Related]
20. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors.
Dromain C; Loaiza-Bonilla A; Mirakhur B; Beveridge TJR; Fojo AT
Oncologist; 2021 Apr; 26(4):e632-e638. PubMed ID: 33393112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]